Circulating tumor DNA biomarkers for response assessment in prostate cancer.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castrate-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA post-treatment can rapidly predict both time to progression and survival.

Keyphrases

circulating tumor
prostate cancer
cell free
circulating tumor cells
radical prostatectomy
small cell lung cancer
squamous cell carcinoma
electronic health record
combination therapy
big data
benign prostatic hyperplasia
free survival
smoking cessation